Loading clinical trials...
Loading clinical trials...
Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Conditions
Interventions
BB-101
Locations
5
Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
Taipei, Taiwan
Wanfang Hospital
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan
Start Date
May 1, 2024
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2028
Last Updated
April 22, 2026
NCT07541196
NCT07039396
NCT07396376
NCT07116876
NCT07198061
NCT07014176
Lead Sponsor
Blue Blood Biotech Corp.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions